Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

October 6, 2017: By Joan McKenna
Alcon's AutonoMe

Alcon’s AutonoMe

Alcon’s AutonoMe preloaded intraocular lens delivery system for its Clareon IOL has gained CE mark approval, parent Novartis announced Oct. 6.

The new device will be introduced with the Clareon IOL at the 2017 meeting of the European Society of Cataract and Refractive Surgeons in Lisbon, Portugal.

“Throughout Alcon’s history, we have worked with doctors to enhance and transform the way cataract surgery is performed,” said Mike Ball, chief executive officer of Alcon, in Fort Worth Texas. “Clareon AutonoMe builds upon the comprehensive legacy of AcrySof by offering cataract surgeons easy, intuitive control of IOL delivery with the newest optic material.”

Features of the AutonoMe include an automated CO2-powered delivery mechanism and an intuitive, ergonomic design to allow precise and simplified single-handed control of IOL placement during cataract surgery, Switzerland-based Novartis said.

The Clareon hydrophobic acrylic IOL, made of a new biomaterial designed to provide sharp vision and optical clarity, received CE mark approval in May.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023